Literature DB >> 36219357

Circ_0082182 upregulates the NFIB level via sponging miR-326 to promote oxaliplatin resistance and malignant progression of colorectal cancer cells.

Zhifeng Wang1, Jingmei Liu2, Tao Yang3, Qinqin Wang4, Rong Liang1, Jinliang Tang5.   

Abstract

Circular RNAs (circRNAs) are key regulators in tumor metastasis and drug resistance. This study was designed to investigate circ_0082182 function and mechanism in oxaliplatin (OXA) resistance and cancer progression of colorectal cancer (CRC). The circ_0082182, microRNA-326 (miR-326), and nuclear factor I B (NFIB) levels were quantified by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Cell sensitization was analyzed by Cell Counting Kit-8 assay. The proliferation ability was determined via EdU assay, and apoptosis was measured by flow cytometry. Transwell assay and wound healing assay were performed to assess cell invasion and migration. The protein level was examined through Western blot. The binding interaction was conducted via dual-luciferase reporter assay. Xenograft tumor assay was used to explore the circ_0082182 function in vivo. The circ_0082182 level was upregulated in OXA-resistant CRC samples and cells. Downregulation of circ_0082182 suppressed OXA resistance, proliferation, invasion, and migration but promoted apoptosis of OXA-resistant CRC cells. Circ_0082182 acted as a sponge for miR-326. The regulatory role of circ_0082182 was ascribed to the miR-326 sponging function. MiR-326 directly targeted NFIB to impede OXA resistance and cancer progression in CRC cells. NFIB level was regulated by circ_0082182 via sponging miR-326. Circ_0082182 promoted tumor growth in OXA-resistant xenograft tumor model through mediating the miR-326/NFIB axis. These data suggested that circ_0082182 elevated the NFIB expression to regulate OXA resistance and CRC progression by absorbing miR-326.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Colorectal cancer; NFIB; Oxaliplatin; circ_0082182; miR-326

Year:  2022        PMID: 36219357     DOI: 10.1007/s11010-022-04551-9

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.842


  32 in total

Review 1.  Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy.

Authors:  Afsane Bahrami; Forouzan Amerizadeh; Seyed Mahdi Hassanian; Soodabeh ShahidSales; Majid Khazaei; Mina Maftouh; Majid Ghayour-Mobarhan; Gordon A Ferns; Amir Avan
Journal:  J Cell Physiol       Date:  2017-05-23       Impact factor: 6.384

Review 2.  Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies.

Authors:  NaNa Keum; Edward Giovannucci
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-08-27       Impact factor: 46.802

Review 3.  Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer.

Authors:  Sorbarikor Piawah; Alan P Venook
Journal:  Cancer       Date:  2019-08-21       Impact factor: 6.860

Review 4.  Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review.

Authors:  Leah H Biller; Deborah Schrag
Journal:  JAMA       Date:  2021-02-16       Impact factor: 56.272

Review 5.  Emerging role of let-7 family in the pathogenesis of hematological malignancies.

Authors:  Fatemeh Yazarlou; Sepideh Kadkhoda; Soudeh Ghafouri-Fard
Journal:  Biomed Pharmacother       Date:  2021-10-13       Impact factor: 6.529

Review 6.  Circular RNAs: The crucial regulatory molecules in colorectal cancer.

Authors:  Kaixuan Zeng; Shukui Wang
Journal:  Pathol Res Pract       Date:  2020-02-11       Impact factor: 3.250

Review 7.  Current and future targets and therapies in metastatic colorectal cancer.

Authors:  Miljana Dzunic; Ivan Petkovic; Ana Cvetanovic; Svetislav Vrbic; Ivica Pejcic
Journal:  J BUON       Date:  2019 Sep-Oct       Impact factor: 2.533

Review 8.  Lessons to Learn for Adequate Targeted Therapy Development in Metastatic Colorectal Cancer Patients.

Authors:  Helena Oliveres; David Pesántez; Joan Maurel
Journal:  Int J Mol Sci       Date:  2021-05-09       Impact factor: 5.923

Review 9.  Drug resistance and new therapies in colorectal cancer.

Authors:  Kevin Van der Jeught; Han-Chen Xu; Yu-Jing Li; Xiong-Bin Lu; Guang Ji
Journal:  World J Gastroenterol       Date:  2018-09-14       Impact factor: 5.742

10.  Casticin inhibits nasopharyngeal carcinoma growth by targeting phosphoinositide 3-kinase.

Authors:  Jingxian Liu; Jinghong Yang; Yuhe Hou; Zhenwei Zhu; Jie He; Hao Zhao; Xidong Ye; Dengke Li; Zhaohui Wu; Zhongxi Huang; Bingtao Hao; Kaitai Yao
Journal:  Cancer Cell Int       Date:  2019-12-21       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.